BiotechTube
Thunder Biotech

Thunder Biotech

Houston, United States· Est.
thunderbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

Thunder Biotech is an early-stage biotech firm pioneering CAR-macrophage (MOTO-CAR) immunotherapy for solid tumors. Founded in 2020 and led by its scientific founder, Dr. Kim O'Neill, the company is in the pre-clinical development stage and is privately funded. It aims to disrupt traditional cancer treatment norms by leveraging engineered macrophages to induce long-term anti-tumor immunity, targeting a significant unmet need in oncology.

Oncology

Technology Platform

MOTO-CAR (Chimeric Antigen Receptor Macrophage) platform, which genetically engineers a patient's own macrophages to express CARs targeting tumor biomarkers, enabling direct tumor killing and engagement of the broader immune system.

Funding History

1
Total raised:$4M
Seed$4M

Opportunities

The massive unmet need in solid tumor treatment represents a multi-billion dollar market opportunity.
Success with its novel CAR-macrophage platform could position Thunder Biotech as a leader in a next-generation cell therapy modality, making it an attractive partner or acquisition target for larger pharmaceutical companies.

Risk Factors

The company faces high scientific risk as its novel macrophage technology is unproven in humans.
Significant financial risk exists as a pre-revenue firm requiring continual capital infusion.
It also operates in an intensely competitive landscape with well-funded rivals pursuing similar myeloid cell approaches.

Competitive Landscape

Thunder Biotech competes in the emerging field of engineered myeloid cell therapy for solid tumors, facing competition from companies like Carisma Therapeutics (NASDAQ: CARM) and Myeloid Therapeutics. It also competes broadly with all solid tumor immunotherapy developers, including those working on next-gen CAR-T, T-cell engagers, and cancer vaccines, many of which have greater resources and more advanced pipelines.

More companies in Diagnostics & Precision Medicine →More companies in United States →